Zobrazeno 1 - 10
of 35
pro vyhledávání: '"Michael J. Millward"'
Autor:
Wee Loong Chin, Rachael M. Zemek, Caitlin M. Tilsed, Alistair R. R. Forrest, Vanessa S. Fear, Catherine Forbes, Louis Boon, Anthony Bosco, Belinda B. Guo, Michael J. Millward, Anna K. Nowak, Richard A. Lake, W. Joost Lesterhuis, Timo Lassmann
Publikováno v:
Scientific Data, Vol 11, Iss 1, Pp 1-9 (2024)
Abstract Time-critical transcriptional events in the immune microenvironment are important for response to immune checkpoint blockade (ICB), yet these events are difficult to characterise and remain incompletely understood. Here, we present whole tum
Externí odkaz:
https://doaj.org/article/a6b9ffd96f4e40b6b71f12cbc7e2efb8
Autor:
Joel Kidman, Rachael M. Zemek, John-William Sidhom, Debora Correa, Nicola Principe, Fezaan Sheikh, Vanessa S. Fear, Catherine A. Forbes, Abha Chopra, Louis Boon, Ayham Zaitouny, Emma de Jong, Robert A. Holt, Matt Jones, Michael J. Millward, Timo Lassmann, Alistair R.R. Forrest, Anna K. Nowak, Mark Watson, Richard A. Lake, W. Joost Lesterhuis, Jonathan Chee
Publikováno v:
OncoImmunology, Vol 13, Iss 1 (2024)
ABSTRACTImmune checkpoint therapy (ICT) causes durable tumour responses in a subgroup of patients, but it is not well known how T cell receptor beta (TCRβ) repertoire dynamics contribute to the therapeutic response. Using murine models that exclude
Externí odkaz:
https://doaj.org/article/f60545e051804f9796499b61db90824e
Autor:
Rachael M. Zemek, Wee Loong Chin, Vanessa S. Fear, Ben Wylie, Thomas H. Casey, Cath Forbes, Caitlin M. Tilsed, Louis Boon, Belinda B. Guo, Anthony Bosco, Alistair R. R. Forrest, Michael J. Millward, Anna K. Nowak, Richard A. Lake, Timo Lassmann, W. Joost Lesterhuis
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-16 (2022)
Immune checkpoint blockade (ICB) is partially successful as a cancer therapy. Here using mouse models, the authors transcriptionally monitor responding and non-responding tumours showing that responding tumours were associated with transient IFN-β s
Externí odkaz:
https://doaj.org/article/59cfc35dd0fb4aa0a34e44f36234b216
Autor:
Sarah J. Dart, Alistair M. Cook, Michael J. Millward, Alison M. McDonnell, Wee L. Chin, Muhammad U. Hakeem, Tarek M. Meniawy, Samantha E. Bowyer
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-11 (2021)
Abstract Advances in cancer immunology have increased the use of immune checkpoint inhibitors in clinical practice, however not all patients respond, and treatment can have severe side-effects. Blood-based immunological biomarkers are an attractive m
Externí odkaz:
https://doaj.org/article/9d283bf0f1db4f83be33e5ef052e4ddd
Autor:
Caitlin M. Tilsed, Thomas H. Casey, Emma de Jong, Anthony Bosco, Rachael M. Zemek, Joanne Salmons, Graeme Wan, Michael J. Millward, Anna K. Nowak, Richard A. Lake, Willem Joost Lesterhuis
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
With immune checkpoint therapy (ICT) having reshaped the treatment of many cancers, the next frontier is to identify and develop novel combination therapies to improve efficacy. Previously, we and others identified beneficial immunological effects of
Externí odkaz:
https://doaj.org/article/19eeddb4bf7541cbb0eb578d199bb0ef
Autor:
Rachael M. Zemek, Wee Loong Chin, Anna K. Nowak, Michael J. Millward, Richard A. Lake, W. Joost Lesterhuis
Publikováno v:
Frontiers in Immunology, Vol 11 (2020)
Immune checkpoint blockade (ICB) has revolutionized cancer treatment, providing remarkable clinical responses in some patients. However, the majority of patients do not respond. It is therefore crucial both to identify predictive biomarkers of respon
Externí odkaz:
https://doaj.org/article/c0ab4303f2fa4686a1db0102b6c02049
Autor:
David S. Hong, Ramon V. Tiu, Michael S. Gordon, Ilaria Conti, Karim A. Benhadji, Sheng-Bin Peng, James R. Henry, Michael D. Kaufman, Daniel L. Flynn, KrisAnne Crowe, Andrew E. Schade, Danni Yu, Melinda D. Willard, Amanda Sykes, Ling Gao, Wei Zhang, Michael J. Millward, Jordi Rodon Ahnert, Geoffrey I. Shapiro, Keith T. Flaherty, Antoine Hollebecque, Ryan J. Sullivan
Supplementary Figure S2 shows two cases of patients treated at the RP2D. IHC at Clarient for p-ERK, p27 and Ki-67 were assessed for PD effect using monoclonal rabbit phospho-p44/42 MAPK (ERK1/2), 20G11 Clone; monoclonal mouse anti-Ki67, MIB-1 clone;
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4bffa344fba1fa66a45a3628b0bc99d4
https://doi.org/10.1158/1535-7163.22521469
https://doi.org/10.1158/1535-7163.22521469
Autor:
Helen Rizos, Georgina V. Long, Richard A. Scolyer, Stephen Q. Wong, Elin S. Gray, Thien Tra, Zeyad Al-Ogaili, Michael J. Millward, Richard F. Kefford, Sarah-Jane Dawson, Russell J. Diefenbach, Alison M. Weppler, Shahneen Sandhu, Ashleigh C. McEvoy, Matteo S. Carlino, Alexander M. Menzies, Jenny H. Lee
Supplementary Figure 1. Flow chart of patient selection. Supplementary Figure 2. Flowchart of patients with disease response assessment available (n = 57).
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4292d69430eaf828060744de34bf6411
https://doi.org/10.1158/1078-0432.22477832.v1
https://doi.org/10.1158/1078-0432.22477832.v1
Autor:
Helen Rizos, Georgina V. Long, Richard A. Scolyer, Stephen Q. Wong, Elin S. Gray, Thien Tra, Zeyad Al-Ogaili, Michael J. Millward, Richard F. Kefford, Sarah-Jane Dawson, Russell J. Diefenbach, Alison M. Weppler, Shahneen Sandhu, Ashleigh C. McEvoy, Matteo S. Carlino, Alexander M. Menzies, Jenny H. Lee
Purpose:Brain involvement occurs in the majority of patients with metastatic melanoma. The potential of circulating tumor DNA (ctDNA) for surveillance and monitoring systemic therapy response in patients with melanoma brain metastases merits investig
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ba7bf0fc2e9ecea51f3667eae8ffc5e7
https://doi.org/10.1158/1078-0432.c.6529769.v1
https://doi.org/10.1158/1078-0432.c.6529769.v1
Autor:
Rachael M. Zemek, Wee Loong Chin, Vanessa S. Fear, Ben Wylie, Thomas H. Casey, Cath Forbes, Caitlin M. Tilsed, Louis Boon, Belinda B. Guo, Anthony Bosco, Alistair R. R. Forrest, Michael J. Millward, Anna K. Nowak, Richard A. Lake, Timo Lassmann, W. Joost Lesterhuis
Publikováno v:
Nature communications. 13(1)
The biological determinants of the response to immune checkpoint blockade (ICB) in cancer remain incompletely understood. Little is known about dynamic biological events that underpin therapeutic efficacy due to the inability to frequently sample tum